Eric Easom - 24 Oct 2022 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ANTX
Reported as of: 24 Oct 2022
Net transaction value: -$147,358
SEC form: 4
Accepted by SEC: 26 Oct 2022, 21:19:30 UTC
Prior SEC filing: 24 Oct 2022
Next SEC filing: 28 Oct 2022
Source filing: View source filing
Reporting owner signature: /s/ Lucy Day, Attorney-in-Fact for Eric Easom

Key filing fact

Eric Easom filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 26 Oct 2022.

Key facts

This page summarizes Eric Easom's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 26 Oct 2022, 21:19.

Change

Previous filing in this sequence was filed on 24 Oct 2022.
Current net transaction value: -$147,358.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANTX transaction

Common Stock

Sale

Transaction value: $46,344
Shares: -2,866
Change %: -20%
Price: $16.17
Shares after: 11,391
Date: 24 Oct 2022
Ownership: Direct
Footnotes: F1

ANTX transaction

Common Stock

Sale

Transaction value: $67,020
Shares: -4,272
Change %: -38%
Price: $15.69
Shares after: 7,119
Date: 25 Oct 2022
Ownership: Direct
Footnotes: F1

ANTX transaction

Common Stock

Sale

Transaction value: $8,652
Shares: -534
Change %: -7.5%
Price: $16.20
Shares after: 6,585
Date: 25 Oct 2022
Ownership: Direct
Footnotes: F1

ANTX transaction

Common Stock

Sale

Transaction value: $25,342
Shares: -1,678
Change %: -25%
Price: $15.10
Shares after: 4,907
Date: 26 Oct 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .